The full list of publications can be found here:


Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

A. S. Petruzzella / E. Oricchio (Dir.)  

Lausanne, EPFL, 2024. 


Cis-regulatory effect of HPV integration is constrained by host chromatin architecture in cervical cancers

A. K. Singh; K. Walavalkar; D. Tavernari; G. Ciriello; D. Notani et al. 

Molecular Oncology. 2023-12-09. DOI : 10.1002/1878-0261.13559.

CellCharter reveals spatial cell niches associated with tissue remodeling and cell plasticity

M. Varrone; D. Tavernari; A. Santamaria-Martinez; L. A. Walsh; G. Ciriello 

Nature Genetics. 2023-12-08. DOI : 10.1038/s41588-023-01588-4.

Whole-genome doubling drives oncogenic loss of chromatin segregation

R. A. Lambuta; L. Nanni; Y. Liu; J. Diaz-Miyar; A. Iyer et al. 

Nature. 2023-03-15. Vol. 615, p. 925–933. DOI : 10.1038/s41586-023-05794-2.

Whole genome doubling promotes tumorigenesis through loss of chromatin segregation and compartment repositioning

R-A. Lambuta / E. Oricchio (Dir.)  

Lausanne, EPFL, 2023. 

Chromatin organization in red triangles

E. Oricchio 

Nature Reviews Genetics. 2023-02-02. DOI : 10.1038/s41576-023-00582-0.


New approaches to uncover the minimally functional hematopoietic niche using the adipocytic differentiation axis: pharmacological modulation and adrenal niche induction

F. Schyrr / E. Oricchio; O. M. Naveiras Torres-Quiroga (Dir.)  

Lausanne, EPFL, 2022. 


Genomic studies indicate a novel combination therapy for follicular lymphoma COMMENT

E. Oricchio; H-G. Wendel 

Molecular & Cellular Oncology. 2021-11-02. Vol. 8, num. 6, p. e969640. DOI : 10.4161/23723548.2014.969640.

De Novo Design of Site-specific Protein Binders Using Surface Fingerprints

S. Wehrle; A. Van Hall-Beauvais; P. Gainza; Z. Harteveld; A. Scheck et al. 

2021-10-01.  p. 162-163.

Cathepsin inhibitors and uses thereof

E. Oricchio; E. Battistello; M. Santin; L. Reymond 

WO2021191412; EP3884948.


Systematic inference and comparison of multi-scale chromatin sub-compartments connects spatial organization to cell phenotypes

Y. Liu; L. Nanni; S. Sungalee; M. Zufferey; D. Tavernari et al. 

Nature Communications. 2021-05-10. Vol. 12, num. 1, p. 2439. DOI : 10.1038/s41467-021-22666-3.

Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression

D. Tavernari; E. Battistello; E. Dheilly; A. S. Petruzzella; M. Mina et al. 

Cancer Discovery. 2021-06-01. Vol. 11, num. 6, p. 1490-1507. DOI : 10.1158/2159-8290.CD-20-1274.

Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci

S. Sungalee; Y. Liu; R. A. Lambuta; N. Katanayeva; M. Donaldson Collier et al. 

Nature Genetics. 2021-05-01. Vol. 53, num. 5, p. 650-662. DOI : 10.1038/s41588-021-00842-x.


The Tumor Microenvironment as a Driving Force of Breast Cancer Stem Cell Plasticity

F. Fico; A. Santamaria-Martinez 

Cancers. 2020-12-01. Vol. 12, num. 12, p. 3863. DOI : 10.3390/cancers12123863.

TGFBI modulates tumour hypoxia and promotes breast cancer metastasis

F. Fico; A. Santamaria-Martinez 

Molecular Oncology. 2020-11-05. Vol. 14, num. 12, p. 3198-3210. DOI : 10.1002/1878-0261.12828.

A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice

P. Roidos; S. Sungalee; S. Benfatto; O. Sercin; A. M. Stuetz et al. 

Nature Communications. 2020-08-14. Vol. 11, num. 1, p. 4077. DOI : 10.1038/s41467-020-17962-3.

Allosteric regulation and targeting of Bruton’s tyrosine kinase (Btk) in B-cell lymphoma

D. Pereira Duarte / E. Oricchio; O. Hantschel (Dir.)  

Lausanne, EPFL, 2020. 

De novo protein design enables the precise induction of RSV-neutralizing antibodies

F. Sesterhenn; C. Yang; J. Bonet; J. T. Cramer; X. Wen et al. 

Science. 2020-05-15. Vol. 368, num. 6492, p. eaay5051730. DOI : 10.1126/science.aay5051.

Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

E. Dheilly; E. Battistello; N. Katanayeva; S. J. Sungalee; J. Michaux et al. 

Cancer Cell. 2020-04-23. Vol. 37, num. 5, p. 674-689.e12. DOI : 10.1016/j.ccell.2020.03.016.

Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells

A. P. Drainas; R. A. Lambuta; I. Ivanova; O. Sercin; I. Sarropoulos et al. 

Cell Reports. 2020-04-07. Vol. 31, num. 1, p. 107465. DOI : 10.1016/j.celrep.2020.03.029.


Histone Modifications in Development and Malignancy

E. Oricchio 

2019-11-13. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, Dec 07-10, 2019. DOI : 10.1182/blood-2019-121289.

EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains

M. C. Donaldson; S. J. Sungalee; M. Zufferey; D. Tavernari; N. Katanayeva et al. 

Nature Genetics. 2019-01-29. Vol. 51, num. March 2019, p. 517–528. DOI : 10.1038/s41588-018-0338-y.

A Tale of Two Tumors: Unraveling the Complexities of Epigenetic Dysregulation in Cancer

M. C. Donaldson / E. Oricchio (Dir.)  

Lausanne, EPFL, 2019. 

Novel therapeutic strategies targeting the B-cell receptor signaling and antigen presentation pathways in non-Hodgkin lymphoma

E. Battistello / E. Oricchio; G. Ciriello (Dir.)  

Lausanne, EPFL, 2019. 


Comparison of computational methods for the identification of topologically associating domains

M. Zufferey; D. Tavernari; E. Oricchio; G. Ciriello 

Genome Biology. 2018-12-10. Vol. 19, p. 217. DOI : 10.1186/s13059-018-1596-9.

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity

E. Dheilly; S. Majocchi; V. Moine; G. Didelot; L. Broyer et al. 

Antibodies. 2018. Vol. 7, num. 1, p. 3. DOI : 10.3390/antib7010003.

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma

E. Battistello; N. Katanayeva; E. Dheilly; D. Tavernari; M. Donaldson et al. 

BLOOD. 2018. Vol. 131, num. 21, p. 2345-2356. DOI : 10.1182/blood-2017-10-809210.


Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies

M. Mina; F. Raynaud; D. Tavernari; E. Battistello; S. Sungalee et al. 

Cancer Cell. 2017. Vol. 32, num. 2, p. 155-+. DOI : 10.1016/j.ccell.2017.06.010.

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma

E. Oricchio; N. Katanayeva; M. C. Donaldson; S. Sungalee; P. P. Joyce et al. 

Science translational medicine. 2017. Vol. 9, num. 396, p. eaak9969. DOI : 10.1126/scitranslmed.aak9969.


Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

M. Boice; D. Salloum; F. Mourcin; V. Sanghvi; R. Amin et al. 

Cell. 2016. Vol. 167, num. 2, p. 405-418.e13. DOI : 10.1016/j.cell.2016.08.032.


Generation and characterization of a single-chain anti-EphA2 antibody

Y. Goldgur; P. Susi; E. Karelehto; H. Sanmark; U. Lamminmäki et al. 

Growth factors (Chur, Switzerland). 2014. Vol. 32, num. 6, p. 214-22. DOI : 10.3109/08977194.2014.983225.

A cell engineering strategy to enhance the safety of stem cell therapies

E. Oricchio; E. P. Papapetrou; F. Lafaille; Y. M. Ganat; S. Kriks et al. 

Cell reports. 2014. Vol. 8, num. 6, p. 1677-85. DOI : 10.1016/j.celrep.2014.08.039.

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

E. Oricchio; G. Ciriello; M. Jiang; M. H. Boice; J. H. Schatz et al. 

The Journal of experimental medicine. 2014. Vol. 211, num. 7, p. 1379-91. DOI : 10.1084/jem.20132120.


Progress against follicular lymphoma

J. H. Schatz; E. Oricchio; S. D. Puvvada; H. G. Wendel 

Current opinion in hematology. 2013. Vol. 20, num. 4, p. 320-6. DOI : 10.1097/MOH.0b013e3283622ed6.

Functional genomics lead to new therapies in follicular lymphoma

E. Oricchio; H-G. Wendel 

Annals of the New York Academy of Sciences. 2013. Vol. 1293, p. 18-24. DOI : 10.1111/nyas.12120.


Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

J. H. Schatz; E. Oricchio; A. L. Wolfe; M. Jiang; I. Linkov et al. 

The Journal of experimental medicine. 2011. Vol. 208, num. 9, p. 1799-807. DOI : 10.1084/jem.20110846.

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma

E. Oricchio; G. Nanjangud; A. L. Wolfe; J. H. Schatz; K. J. Mavrakis et al. 

Cell. 2011. Vol. 147, num. 3, p. 554-64. DOI : 10.1016/j.cell.2011.09.035.